<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528199</url>
  </required_header>
  <id_info>
    <org_study_id>J19145</org_study_id>
    <secondary_id>IRB00231620</secondary_id>
    <nct_id>NCT04528199</nct_id>
  </id_info>
  <brief_title>[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer</brief_title>
  <official_title>A Phase 1 Study of [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FutureChem</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open label, single-arm study designed to evaluate the safety and diagnostic&#xD;
      performance of [18F]FLOR (FC303) PET/CT imaging to determine the presence or absence of&#xD;
      metastatic prostate cancer. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done to determine whether the radioactive compound called [18F]FLOR&#xD;
      (FC303) is safe and well-tolerated in patients with metastatic prostate cancer.&#xD;
&#xD;
      Participants in this study will have tests, exams and procedures that are for study purposes.&#xD;
      Participants will be in this study up to one month which will include up to three clinic&#xD;
      visits.&#xD;
&#xD;
      Eligible patients diagnosed with metastatic prostate cancer will undergo a [18F]FLOR (FC303)&#xD;
      PET-CT scan. This is the imaging procedure to assess where [18F]FLOR (FC303) has accumulated&#xD;
      in the body.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of study drug emergent adverse events</measure>
    <time_frame>Up to 10 days post-study drug dosing</time_frame>
    <description>Incidence of study drug emergent adverse events will be assessed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>[18F]FLOR (FC303)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]FLOR (FC303) PET/CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FLOR (FC303) Injection</intervention_name>
    <description>Single dose of 10 ±1 millicurie (mCi) of [18F]FLOR (FC303) injection followed by the PET/CT scan.</description>
    <arm_group_label>[18F]FLOR (FC303)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males ≥18 years of age.&#xD;
&#xD;
          -  Subjects provide signed informed consent and confirm that they are able and willing to&#xD;
             comply with all protocol requirements.&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate.&#xD;
&#xD;
          -  Radiologic evidence of local recurrence or new or progressive metastatic disease&#xD;
             demonstrated on anatomical imaging (CT, or MRI), or whole-body bone scan within 4&#xD;
             weeks of Day 1.&#xD;
&#xD;
          -  At least 2 weeks must have elapsed between last anti-cancer treatment administration&#xD;
             and the imaging day. Imaging day will be scheduled before initiation of new systemic&#xD;
             therapy for recurrent and/or progressive metastatic disease&#xD;
&#xD;
          -  Screening clinical laboratory values within normal limits or judged not clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects administered any radioisotope within five physical half-lives prior to study&#xD;
             drug injection.&#xD;
&#xD;
          -  Subjects with any medical condition or other circumstances that, in the opinion of the&#xD;
             investigator, compromise obtaining reliable data, achieving study objectives, or&#xD;
             completion.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Rowe, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary K Brosnan, BA</last_name>
    <phone>410-955-8264</phone>
    <email>mbrosna1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rehab AbdAllah, MB BCH</last_name>
    <phone>410-955-6615</phone>
    <email>rabdall1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary K Brosnan, BA</last_name>
      <phone>410-955-8264</phone>
      <email>mbrosna1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rehab Abdallah, MB BCh</last_name>
      <phone>410-955-6615</phone>
      <email>rabdall1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Pomper, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>[18F]FLOR</keyword>
  <keyword>PET/CT</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>J19145</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

